Technical Report No. 81

Cell-Based Therapy Control Strategy

PDA Cell-Based Therapy Control Strategy Technical Report Team

Authors

Valérie Pimpaneau, Voisin Consulting, Co-Chair

Jean Stanton, Johnson and Johnson., Co-Chair

Michael Blackton, Adaptimmune LLC

Vijay Chiruvolu, PhD, Kite Pharma

Fabio D'Agostino, PhD, Newcastle University

Margit Jeschke, PhD, Novartis

Michele Myers, PhD, GlaxoSmithKline

Audra Riley, NewLink Genetics

Mercedes Segura, Ph.D., bluebird bio

Contributors

Richard Dennett, Voisin Consulting

Ricardo Jimenez, Lonza Houston, Inc.

Bernadette Keane, PhD, Keane Consulting

Mark Leney, PhD, ClearPath Development Company

Maria del Pilar Redondo, TiGenix

Kirstin Powel, Novartis

Karen Walker, Seattle Genetics

Cell-Based Therapy Control Strategy

Technical Report No. 21

ISBN 978-1-945384-06-0

PDA®
Parenteral Drug Association

Table of Contents

1.0 Introduction....1

1.1 Scope and Purpose....2
1.2 Background....3

2.0 Glossary and Abbreviations....5

2.1 Abbreviations....5

3.0 Product Profile....5

3.1 Target Product Profile....5
3.2 Quality Target Product Profile....7
3.3 TPP and QTPP for A-CeT....8

4.0 Critical Quality Attributes....10

4.1 Criticality Assessment....11
4.2 CQAs for A-CeT....12
4.2.1 Visual Appearance....12
4.2.2 Identity....12
4.2.3 Impurities....14
4.2.4 Potency....14
4.2.5 Strength/Dose....14
4.2.6 Safety....14

5.0 Critical Process Parameters....15

5.1 Identification of Process Parameters (Step 1)....15
5.1.1 Process Mapping for A-CeT....15
5.2 Parameter Criticality Assessment (Step 2)....17
5.2.1 Parameter Criticality Assessment for A-CeT....17
5.3 Parameter Risk (or Process Capability) Assessment (Step 3)....19
5.3.1 Process Capability Assessment for A-CeT....20
5.4 Process Performance Assessment....20

6.0 Critical Material Attributes....21

6.1 Identification of Raw Materials (Step 1)....21
6.2 Criticality Assessment (Step 2)....22
6.3 Raw Material Risk (or Process Capability) Assessment (Step 3)....23

7.0 CONTROL STRATEGY....25

7.1 Process Parameters Controls....26
7.2 Material Attribute Controls....27
7.2.1 Raw Materials....27
7.2.2 Primary Cells as Starting Materials....28
7.2.2.1 Vectors as Starting Materials....29
7.2.3 Components....29
7.3 Procedural Controls....30
7.3.1 Aseptic Manual Processing....30
7.3.2 Personnel....30
7.3.3 Environmental Monitoring....31
7.3.4 Facilities and Equipment....32
7.3.5 Advantages to Using Isolators and Automation....32
7.4 Testing Controls....32
7.4.1 Product Release Specification....33
7.4.1.1 Identity....33
7.4.1.2 Potency....33
7.4.1.3 Purity....34
7.4.1.4 Safety....34
7.4.1.5 Dose....35
7.4.2 In-Process Testing....35
7.4.3 Characterization....36
7.4.4 Process Monitoring....37
7.5 A-CeT Manufacturing Control Strategy....37
7.5.1 Control Strategy Summary for A-CeT....42
7.5.1.1 Material Attribute Controls for A-CeT....42
7.5.1.2 Procedural Controls for A-CeT....43
7.5.1.3 Process Parameter Controls for A-CeT....43

8.0 Lifecycle Management....44

9.0 Summary....44

10.0 References....46

FIGURES AND TABLES INDEX

Figure 1.0-1 Process Flow Diagram for A-CeT 2

Table 3.1-1 Points to Consider for the Development of the TPP 6

Table 3.2-1 Points to Consider for QTPPs 8

Table 3.3-1 Sample TPP for A-CeT 9

Table 3.3-2 Sample QTPP for A-CeT 9

Table 4.1-1 Impact (Severity) Assessment 12

Table 4.1-2 Criteria for Uncertainty Scoring of Product Attributes 12

Table 4.1-3 Product Attribute Criticality Assessment 12

Table 4.2.3-1 Example Criticality Assessment Results for A-CeT 13

Table 5.1.1-1 IPO Diagram for A-CeT Cell Culture Expansion Step 16

Table 5.2-1 Process Parameter Severity Scoring 17

Table 5.2.1-1 Parameter Criticality Assessment for Culture Expansion Step of A-CeT CQAs 18

Table 5.3-1 Criteria for Occurrence Assessment 19

Table 5.3-2 Criteria for Detection Assessment 19

Table 5.3.1-1 Quantitative Impact Process Parameters of Culture Expansion Step on A-CeT CQAs 20

Figure 6.0-1 Assessments Required to Contribute to Overall Raw Material Control Strategy 21

Figure 6.1-1 Materials Used in the Manufacturing of an Autologous Cartilage Cell Product 22

Table 6.2-1 Raw Materials Impact Classification 22

Table 6.2-2 Process Reagents Criticality Assessment of Culture Expansion Step on A-CeT CQAs 23

Table 6.3-1 Occurrence Scoring for Raw Materials 24

Table 6.3-2 Detection Scoring for Raw Materials 24

Table 6.3-3 Quantitative Impact of Process Reagents for Culture Expansion Step on A-CeT CQAs 25

Figure 7.0-1 Schematic Control Strategy Development 26

Figure 7.0-2 Specific Elements of Control Strategy Components 26

Figure 7.3.3-1 Foundation for Environmental Monitoring Program 31

Table 7.4.3-1 Examples of Characterization Testing 36

Table 7.5-1 Implementation of Risk-based Tools for A-CeT 38

Figure 7.5-1 Decision Tree for Parameter or Material Criticality Assessment (PMCA) 38

Figure 7.5-2 Decision Tree for Parameter Capability Assessment 38

Table 7.5-2 Example of Elements of the A-CET Control Strategy for Safety CQA 39

Table 7.5-3 Testing Plan for A-CeT 42

Figure 9.0-1 Overarching Strategy for Risk-based Approach 45

Figure 9.0-2 Control Strategy for Critical Quality Attributes 45